Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Labcorp Holdings (N6B) Stock Price & Analysis

N6B Stock Chart & Stats

€324.00€0.00(0.00%)
At close: 5:30 PM GMT+1
EUR 250EUR 275EUR 300EUR 32530 Jul20 Aug8 Sep28 Sep15 Oct28 Oct
Day’s Range
EUR 324.00 - EUR 328.00
52-Week Range
EUR 212.00 - EUR 328.00
Previous Close
EUR 324.00
Volume
0
Average Volume (3M)
2
Market Cap
EUR 26.16B
Enterprise Value
EUR 31.67B
Total Cash (Recent Filing)
EUR 261.80M
Total Debt (Recent Filing)
EUR 6.78B
Price to Earnings (P/E)
29.5
Beta
0.34
Next Earnings
Feb 11, 2027 (Est.)
EPS Estimate
4.03
Next Dividend Ex-Date
N/A
Dividend Yield
0.77%

Bulls Say, Bears Say

Bulls Say

Broad-based Growth And Margin Expansion

Growth is broad enough to support durable operating improvement rather than relying on a single product or customer. Revenue expansion combined with higher margins indicates operating leverage and productivity benefits, strengthening the company’s ability to grow earnings and cash flow over the next several quarters.

Biopharma Laboratory Backlog

The large BLS backlog provides meaningful visibility into future revenue conversion and supports the durability of the drug-development services franchise. Strong book-to-bill and double-digit organic growth also indicate sustained demand from biopharma customers, while expanded laboratory capacity can support continued execution.

Specialty Diagnostics And Innovation

Faster specialty-testing growth can improve Labcorp’s mix and deepen physician relationships because specialty orders often generate additional core laboratory testing. FDA-cleared and approved offerings in oncology, neurology, and precision medicine broaden the company’s differentiated platform and support longer-term relevance.

Bears Say

PAMA Reimbursement Pressure

The proposed reimbursement reductions represent a structural pressure on the diagnostics business rather than a temporary fluctuation. Lower Medicare and Medicaid rates could compress revenue and margins across multiple years, requiring productivity savings, growth, and mix improvement to preserve the company’s earnings trajectory.

Meaningful Leverage

Although leverage has improved from 2024–2025, the debt load remains a meaningful fixed obligation relative to equity. This reduces balance-sheet flexibility and makes sustained earnings and cash generation important for continued deleveraging, acquisitions, capital returns, and resilience if operating conditions weaken.

Moderate Cash Conversion And Below-peak Margins

Labcorp generates substantial absolute cash, but cash conversion is not fully keeping pace with reported earnings, limiting internal funding efficiency. Profitability has recovered from 2023 yet remains below prior peaks, so additional execution is needed before the business can demonstrate fully restored margin durability.

Labcorp Holdings News

N6B FAQ

What was Labcorp Holdings’s price range in the past 12 months?
Labcorp Holdings lowest stock price was €212.00 and its highest was €328.00 in the past 12 months.
What is Labcorp Holdings’s market cap?
Labcorp Holdings’s market cap is €26.16B.
When is Labcorp Holdings’s upcoming earnings report date?
Labcorp Holdings’s next earnings report is estimated for Feb 11, 2027 (not yet confirmed), which is in 101 days.
How were Labcorp Holdings’s earnings last quarter?
Labcorp Holdings released its earnings results on Oct 28, 2026. The company reported €4.268 earnings per share for the quarter, beating the consensus estimate of €4.146 by €0.121.
Is Labcorp Holdings overvalued?
According to Wall Street analysts Labcorp Holdings’s price is currently Undervalued.
Does Labcorp Holdings pay dividends?
Labcorp Holdings does not currently pay dividends.
What is Labcorp Holdings’s EPS estimate?
Labcorp Holdings’s EPS estimate is 4.03.
How many shares outstanding does Labcorp Holdings have?
Labcorp Holdings has 81,100,000 shares outstanding.
What happened to Labcorp Holdings’s price movement after its last earnings report?
Labcorp Holdings reported an EPS of €4.268 in its last earnings report, beating expectations of €4.146. Following the earnings report the stock price went up 11.565%.
Which hedge fund is a major shareholder of Labcorp Holdings?
Hedge funds hold Labcorp Holdings shares: the largest hedge-fund position in Labcorp Holdings is 2,146,643,341 shares, and hedge funds decreased their holdings by 104.1K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology